

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
May 6, 2015**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Tekmira Pharmaceuticals Corporation

File No. 001-34949 - CF#32241

Tekmira Pharmaceuticals Corporation submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the exhibits to a Form 10-K filed on March 13, 2015 as amended.

Based on representations by Tekmira Pharmaceuticals Corporation that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.41	through March 1, 2020
Exhibit 10.42	through March 12, 2025
Exhibit 10.46	through September 1, 2020
Exhibit 10.49	through September 1, 2020
Exhibit 10.54	through September 1, 2020
Exhibit 10.64	through September 1, 2020
Exhibit 10.65	through September 1, 2020
Exhibit 10.67	through September 1, 2020
Exhibit 10.68	through September 1, 2020
Exhibit 10.70	through September 1, 2020
Exhibit 10.72	through September 1, 2020
Exhibit 10.74	through September 1, 2020
Exhibit 10.75	through September 1, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary